Inocras

Executive Summary

Inocras, founded in 2019 and headquartered in San Diego, is a clinical genomics company specializing in whole genome sequencing (WGS) for cancer and rare disease diagnosis. The company operates a CAP/CLIA-certified laboratory offering rapid-turnaround tests that provide comprehensive genomic insights, often detecting variants missed by targeted panels or exome sequencing. By leveraging advanced bioinformatics, Inocras aims to transform diagnostic precision and therapeutic decision-making for complex genetic conditions. The company is currently in an early commercial stage, focusing on building clinical validation and expanding its test menu to address unmet needs in oncology and rare diseases. Inocras differentiates itself by delivering a more complete genomic picture compared to standard approaches, which can reduce the diagnostic odyssey for patients and uncover actionable variants. The company’s tests are designed for rapid turnaround, enabling timely clinical interventions. As the adoption of WGS grows, Inocras is well-positioned to capture market share through its curated reporting and scalable platform. Near-term priorities include publishing clinical utility data, forming strategic partnerships with healthcare institutions, and expanding reimbursement coverage. With a growing emphasis on precision medicine, Inocras has the potential to become a key player in the genomic diagnostics landscape.

Upcoming Catalysts (preview)

• Q4 2026Launch of Comprehensive WGS Test for Rare Pediatric Diseases70% success
• Q3 2026Strategic Partnership with a Major Cancer Center for Clinical Trial Use80% success
• Q4 2026Presentation of Validation Data at a Major Genomics Conference90% success